4.5 Review

Updating the Natural History of Human Papillomavirus and Anogenital Cancers

Journal

VACCINE
Volume 30, Issue -, Pages F24-F33

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2012.05.089

Keywords

HPV; Natural history; Transmission; Male infections; Anal disease

Funding

  1. US Public Health Service (National Cancer Institute, National Institutes of Health, Department of Health and Human Services) [R37 CA51323, NIH R01 CA098803, R01 CA077318, R01 CA 88739, R01 CA54053]
  2. Canadian Institutes of Health Research
  3. European Commission [HEALTH-F3-2010-242061]
  4. Instituto de Salud Carlos III [FIS PI08/1535, RCESP C03/09, RTICESP C03/10, RTIC RD06/0020/0095, CIBERESP]
  5. Agencia de Gestio, d'Ajuts Universitaris i de Recerca [AGAUR 2005SGR00695, AGAUR 2009SGR126]
  6. GenProbe
  7. Bectin Dickinson
  8. Merck Canada Ltd.
  9. Qiagen
  10. GlaxoSmithKline
  11. Merck
  12. Sanofi Pasteur MSD
  13. Roche
  14. GSK
  15. Merck Co., Inc.

Ask authors/readers for more resources

This chapter addresses the natural history of anogenital human papillomavirus (HPV) infection. Cervical infections are the best understood HPV infection. Cervical HPV persistence is the known necessary event for the development of cervical cancer. New infections appearing at any age are benign unless they persist. Several long-term natural history studies have now shed light on the very low risk of cervical intraepithelial neoplasia (CIN) 3+ in women past the peak of HPV acquisition (e.g., 30 or older) who are HPV-negative or clear their HPV. Although data on transmission of HPV are finally emerging, rates of transmission between heterosexual couples vary widely among studies. Factors that affect the calculations of these rates include a) intervals between testing points, b) rates of concordance or discordance at baseline, and c) difficulty in defining established infections versus contamination. Both cervix to anus and anus to cervix autoinoculation in the same woman appears to be quite common. Whether either site serves as a long-term reservoir is unknown. Studies show that anal infections in women and in men who have sex with men are quite common with cumulative rates up to 70-90%. Similarly, clearance of anal HPV is also common, with few individuals showing persistence unless they are human immunodeficiency virus (HIV)-infected. HIV strongly influences the development of anal intraepithelial neoplasia (AIN). The few studies on the natural history of AIN in HIV-infected men suggest that high-grade AIN is a precursor to invasive anal cancer. Although no natural history studies of AIN are available in women, women with other HPV-associated lesions, including CIN3+ and vulvar cancer, have higher rates of anal cancer. Data on the natural history of HPV of the male genitalia are also emerging, although penile intraepithelial neoplasia is poorly understood. Cumulative rates of HPV are extremely high in men and risks are associated with sexual behavior. Unlike women, prevalence rates are steady across all ages, suggesting that men do not develop protection against reinfection. This article forms part of a special supplement entitled Comprehensive Control of HPV Infections and Related Diseases Vaccine Volume 30, Supplement 5, 2012. (C) 2012 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available